Which has preferable earnings and valuation, CNTB or ANL?

Adlai Nortye has higher revenue and earnings than Connect Biopharma. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Connect Biopharma $60K 2,340.39 -$55.48M -$1.19 N/A Adlai Nortye $5M 110.56 -$35.53M N/A N/A

Is CNTB or ANL more profitable?

Adlai Nortye's return on equity of 0.00% beat Connect Biopharma's return on equity. Company Net Margins Return on Equity Return on Assets Connect Biopharma N/A -165.41% -121.58% Adlai Nortye N/A N/A N/A

Does the media refer more to CNTB or ANL?

In the previous week, Adlai Nortye had 10 more articles in the media than Connect Biopharma. MarketBeat recorded 12 mentions for Adlai Nortye and 2 mentions for Connect Biopharma. Connect Biopharma's average media sentiment score of 0.94 beat Adlai Nortye's score of 0.53 indicating that Connect Biopharma is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Connect Biopharma 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Adlai Nortye 4 Very Positive mention(s) 2 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Is ARTV or CNTB more profitable?

Artiva Biotherapeutics' return on equity of -53.86% beat Connect Biopharma's return on equity. Company Net Margins Return on Equity Return on Assets Artiva Biotherapeutics N/A -53.86% -48.16% Connect Biopharma N/A -165.41% -121.58%

Does the media prefer ARTV or CNTB?

In the previous week, Artiva Biotherapeutics had 5 more articles in the media than Connect Biopharma. MarketBeat recorded 7 mentions for Artiva Biotherapeutics and 2 mentions for Connect Biopharma. Artiva Biotherapeutics' average media sentiment score of 1.14 beat Connect Biopharma's score of 0.94 indicating that Artiva Biotherapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Artiva Biotherapeutics 4 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Connect Biopharma 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Is CABA or CNTB more profitable?

Cabaletta Bio's return on equity of -128.27% beat Connect Biopharma's return on equity. Company Net Margins Return on Equity Return on Assets Cabaletta Bio N/A -128.27% -95.47% Connect Biopharma N/A -165.41% -121.58%

Does the media refer more to CABA or CNTB?

In the previous week, Cabaletta Bio had 3 more articles in the media than Connect Biopharma. MarketBeat recorded 5 mentions for Cabaletta Bio and 2 mentions for Connect Biopharma. Cabaletta Bio's average media sentiment score of 1.23 beat Connect Biopharma's score of 0.94 indicating that Cabaletta Bio is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Cabaletta Bio 1 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Connect Biopharma 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media refer more to PROK or CNTB?

In the previous week, ProKidney and ProKidney both had 2 articles in the media. ProKidney's average media sentiment score of 0.94 equaled Connect Biopharma'saverage media sentiment score. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment ProKidney 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Connect Biopharma 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Is CNTB or ZURA more profitable?

Zura Bio's return on equity of -56.13% beat Connect Biopharma's return on equity. Company Net Margins Return on Equity Return on Assets Connect Biopharma N/A -165.41% -121.58% Zura Bio N/A -56.13% -50.15%

Does the media prefer CNTB or ZURA?

In the previous week, Zura Bio had 2 more articles in the media than Connect Biopharma. MarketBeat recorded 4 mentions for Zura Bio and 2 mentions for Connect Biopharma. Zura Bio's average media sentiment score of 1.09 beat Connect Biopharma's score of 0.94 indicating that Zura Bio is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Connect Biopharma 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Zura Bio 2 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Connect Biopharma (CNTB) Competitors

$2.23 -0.05 (-2.19%)

As of 08/28/2026 04:00 PM Eastern

Compare

CNTB vs. ANL, ARTV, CABA, PROK, and ZURA

Should you buy Connect Biopharma stock or one of its competitors? Connect Biopharma's main competitors and comparable companies include Adlai Nortye (ANL), Artiva Biotherapeutics (ARTV), Cabaletta Bio (CABA), ProKidney (PROK), and Zura Bio (ZURA). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does Connect Biopharma compare to Adlai Nortye?

Connect Biopharma (NASDAQ:CNTB) and Adlai Nortye (NASDAQ:ANL) are both small-cap healthcare companies, but which is the better stock? We will compare the two businesses based on the strength of their profitability, risk, media sentiment, earnings, dividends, analyst recommendations, institutional ownership and valuation.

Adlai Nortye has higher revenue and earnings than Connect Biopharma.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Connect Biopharma	$60K	2,340.39	-$55.48M	-$1.19	N/A
Adlai Nortye	$5M	110.56	-$35.53M	N/A	N/A

In the previous week, Adlai Nortye had 10 more articles in the media than Connect Biopharma. MarketBeat recorded 12 mentions for Adlai Nortye and 2 mentions for Connect Biopharma. Connect Biopharma's average media sentiment score of 0.94 beat Adlai Nortye's score of 0.53 indicating that Connect Biopharma is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Connect Biopharma	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Adlai Nortye	4 Very Positive mention(s)	2 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Adlai Nortye's return on equity of 0.00% beat Connect Biopharma's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Connect Biopharma	N/A	-165.41%	-121.58%
Adlai Nortye	N/A	N/A	N/A

Connect Biopharma has a beta of -0.23, meaning that its share price is 123% less volatile than the broader market. Comparatively, Adlai Nortye has a beta of 1.06, meaning that its share price is 6% more volatile than the broader market.

Connect Biopharma currently has a consensus target price of $7.43, indicating a potential upside of 233.12%. Adlai Nortye has a consensus target price of $24.25, indicating a potential upside of 75.47%. Given Connect Biopharma's stronger consensus rating and higher probable upside, analysts clearly believe Connect Biopharma is more favorable than Adlai Nortye.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Connect Biopharma	1 Sell rating(s)	0 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.75
Adlai Nortye	1 Sell rating(s)	0 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.67

58.7% of Connect Biopharma shares are held by institutional investors. Comparatively, 35.2% of Adlai Nortye shares are held by institutional investors. 22.6% of Connect Biopharma shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Summary

Connect Biopharma beats Adlai Nortye on 7 of the 13 factors compared between the two stocks.

How does Connect Biopharma compare to Artiva Biotherapeutics?

Artiva Biotherapeutics (NASDAQ:ARTV) and Connect Biopharma (NASDAQ:CNTB) are both small-cap healthcare companies, but which is the better investment? We will compare the two businesses based on the strength of their earnings, institutional ownership, profitability, analyst recommendations, risk, valuation, dividends and media sentiment.

Connect Biopharma has lower revenue, but higher earnings than Artiva Biotherapeutics. Artiva Biotherapeutics is trading at a lower price-to-earnings ratio than Connect Biopharma, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Artiva Biotherapeutics	$250K	2,168.76	-$83.86M	-$3.30	N/A
Connect Biopharma	$60K	2,340.39	-$55.48M	-$1.19	N/A

Artiva Biotherapeutics has a beta of 2.16, suggesting that its stock price is 116% more volatile than the broader market. Comparatively, Connect Biopharma has a beta of -0.23, suggesting that its stock price is 123% less volatile than the broader market.

Artiva Biotherapeutics presently has a consensus target price of $39.00, suggesting a potential upside of 251.67%. Connect Biopharma has a consensus target price of $7.43, suggesting a potential upside of 233.12%. Given Artiva Biotherapeutics' stronger consensus rating and higher probable upside, equities research analysts clearly believe Artiva Biotherapeutics is more favorable than Connect Biopharma.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Artiva Biotherapeutics	1 Sell rating(s)	0 Hold rating(s)	4 Buy rating(s)	1 Strong Buy rating(s)	2.83
Connect Biopharma	1 Sell rating(s)	0 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.75

Artiva Biotherapeutics' return on equity of -53.86% beat Connect Biopharma's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Artiva Biotherapeutics	N/A	-53.86%	-48.16%
Connect Biopharma	N/A	-165.41%	-121.58%

58.7% of Connect Biopharma shares are held by institutional investors. 1.8% of Artiva Biotherapeutics shares are held by insiders. Comparatively, 22.6% of Connect Biopharma shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

In the previous week, Artiva Biotherapeutics had 5 more articles in the media than Connect Biopharma. MarketBeat recorded 7 mentions for Artiva Biotherapeutics and 2 mentions for Connect Biopharma. Artiva Biotherapeutics' average media sentiment score of 1.14 beat Connect Biopharma's score of 0.94 indicating that Artiva Biotherapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Artiva Biotherapeutics	4 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Connect Biopharma	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Artiva Biotherapeutics beats Connect Biopharma on 9 of the 16 factors compared between the two stocks.

How does Connect Biopharma compare to Cabaletta Bio?

Cabaletta Bio (NASDAQ:CABA) and Connect Biopharma (NASDAQ:CNTB) are both small-cap healthcare companies, but which is the better stock? We will contrast the two businesses based on the strength of their risk, valuation, media sentiment, analyst recommendations, profitability, earnings, dividends and institutional ownership.

58.7% of Connect Biopharma shares are owned by institutional investors. 6.4% of Cabaletta Bio shares are owned by insiders. Comparatively, 22.6% of Connect Biopharma shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Connect Biopharma has higher revenue and earnings than Cabaletta Bio. Cabaletta Bio is trading at a lower price-to-earnings ratio than Connect Biopharma, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Cabaletta Bio	N/A	N/A	-$167.86M	-$1.57	N/A
Connect Biopharma	$60K	2,340.39	-$55.48M	-$1.19	N/A

Cabaletta Bio's return on equity of -128.27% beat Connect Biopharma's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Cabaletta Bio	N/A	-128.27%	-95.47%
Connect Biopharma	N/A	-165.41%	-121.58%

Cabaletta Bio has a beta of 3.3, suggesting that its stock price is 230% more volatile than the broader market. Comparatively, Connect Biopharma has a beta of -0.23, suggesting that its stock price is 123% less volatile than the broader market.

Cabaletta Bio currently has a consensus target price of $15.33, indicating a potential upside of 391.45%. Connect Biopharma has a consensus target price of $7.43, indicating a potential upside of 233.12%. Given Cabaletta Bio's higher probable upside, analysts clearly believe Cabaletta Bio is more favorable than Connect Biopharma.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Cabaletta Bio	1 Sell rating(s)	1 Hold rating(s)	5 Buy rating(s)	1 Strong Buy rating(s)	2.75
Connect Biopharma	1 Sell rating(s)	0 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.75

In the previous week, Cabaletta Bio had 3 more articles in the media than Connect Biopharma. MarketBeat recorded 5 mentions for Cabaletta Bio and 2 mentions for Connect Biopharma. Cabaletta Bio's average media sentiment score of 1.23 beat Connect Biopharma's score of 0.94 indicating that Cabaletta Bio is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Cabaletta Bio	1 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Connect Biopharma	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Cabaletta Bio and Connect Biopharma tied by winning 7 of the 14 factors compared between the two stocks.

How does Connect Biopharma compare to ProKidney?

ProKidney (NASDAQ:PROK) and Connect Biopharma (NASDAQ:CNTB) are both small-cap healthcare companies, but which is the superior business? We will compare the two businesses based on the strength of their analyst recommendations, risk, media sentiment, earnings, institutional ownership, valuation, dividends and profitability.

In the previous week, ProKidney and ProKidney both had 2 articles in the media. ProKidney's average media sentiment score of 0.94 equaled Connect Biopharma'saverage media sentiment score.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
ProKidney	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Connect Biopharma	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

ProKidney currently has a consensus price target of $12.00, suggesting a potential upside of 555.74%. Connect Biopharma has a consensus price target of $7.43, suggesting a potential upside of 233.12%. Given ProKidney's higher possible upside, equities research analysts plainly believe ProKidney is more favorable than Connect Biopharma.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
ProKidney	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	1 Strong Buy rating(s)	2.67
Connect Biopharma	1 Sell rating(s)	0 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.75

Connect Biopharma has a net margin of 0.00% compared to ProKidney's net margin of -10,288.39%. ProKidney's return on equity of 0.00% beat Connect Biopharma's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
ProKidney	-10,288.39%	N/A	-27.39%
Connect Biopharma	N/A	-165.41%	-121.58%

ProKidney has a beta of 1.66, suggesting that its stock price is 66% more volatile than the broader market. Comparatively, Connect Biopharma has a beta of -0.23, suggesting that its stock price is 123% less volatile than the broader market.

Connect Biopharma has lower revenue, but higher earnings than ProKidney. ProKidney is trading at a lower price-to-earnings ratio than Connect Biopharma, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
ProKidney	$890K	621.62	-$68.99M	-$0.55	N/A
Connect Biopharma	$60K	2,340.39	-$55.48M	-$1.19	N/A

51.6% of ProKidney shares are held by institutional investors. Comparatively, 58.7% of Connect Biopharma shares are held by institutional investors. 39.8% of ProKidney shares are held by company insiders. Comparatively, 22.6% of Connect Biopharma shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Summary

ProKidney beats Connect Biopharma on 8 of the 15 factors compared between the two stocks.

How does Connect Biopharma compare to Zura Bio?

Connect Biopharma (NASDAQ:CNTB) and Zura Bio (NASDAQ:ZURA) are both small-cap healthcare companies, but which is the better business? We will contrast the two companies based on the strength of their risk, analyst recommendations, valuation, media sentiment, institutional ownership, earnings, profitability and dividends.

In the previous week, Zura Bio had 2 more articles in the media than Connect Biopharma. MarketBeat recorded 4 mentions for Zura Bio and 2 mentions for Connect Biopharma. Zura Bio's average media sentiment score of 1.09 beat Connect Biopharma's score of 0.94 indicating that Zura Bio is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Connect Biopharma	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Zura Bio	2 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Connect Biopharma has higher revenue and earnings than Zura Bio. Zura Bio is trading at a lower price-to-earnings ratio than Connect Biopharma, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Connect Biopharma	$60K	2,340.39	-$55.48M	-$1.19	N/A
Zura Bio	N/A	N/A	-$99.35M	-$1.13	N/A

Connect Biopharma has a beta of -0.23, suggesting that its share price is 123% less volatile than the broader market. Comparatively, Zura Bio has a beta of -0.02, suggesting that its share price is 102% less volatile than the broader market.

Zura Bio's return on equity of -56.13% beat Connect Biopharma's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Connect Biopharma	N/A	-165.41%	-121.58%
Zura Bio	N/A	-56.13%	-50.15%

Connect Biopharma presently has a consensus price target of $7.43, suggesting a potential upside of 233.12%. Zura Bio has a consensus price target of $17.00, suggesting a potential upside of 197.20%. Given Connect Biopharma's higher probable upside, research analysts plainly believe Connect Biopharma is more favorable than Zura Bio.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Connect Biopharma	1 Sell rating(s)	0 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.75
Zura Bio	1 Sell rating(s)	0 Hold rating(s)	5 Buy rating(s)	1 Strong Buy rating(s)	2.86

58.7% of Connect Biopharma shares are held by institutional investors. Comparatively, 61.1% of Zura Bio shares are held by institutional investors. 22.6% of Connect Biopharma shares are held by insiders. Comparatively, 12.4% of Zura Bio shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Summary

Zura Bio beats Connect Biopharma on 9 of the 15 factors compared between the two stocks.

Get Connect Biopharma News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding CNTB and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

CNTB vs. The Competition

Export

Metric	Connect Biopharma	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$140.43M	$3.94B	$7.21B	$12.91B
Dividend Yield	N/A	3.61%	2.54%	11.28%
P/E Ratio	-1.87	11.62	273.16	25.42
Price / Sales	2,340.39	1,314.79	615.35	86.95
Price / Cash	N/A	106.39	76.74	53.00
Price / Book	5.19	16.53	12.98	6.14
Net Income	-$55.48M	-$22.80M	$3.48B	$348.86M
7 Day Performance	-5.51%	-0.31%	0.13%	-0.80%
1 Month Performance	6.70%	9.80%	7.08%	4.13%
1 Year Performance	8.25%	55.66%	24.67%	15.17%

Connect Biopharma Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
CNTB Connect Biopharma	4.2563 of 5 stars	$2.23 -2.2%	$7.43 +233.1%	+8.3%	$140.43M	$60K	N/A	110	News Coverage
ANL Adlai Nortye	1.7901 of 5 stars	$13.84 -3.4%	$24.25 +75.2%	+717.8%	$553.60M	$5M	N/A	127	News Coverage
ARTV Artiva Biotherapeutics	3.1487 of 5 stars	$11.27 -5.6%	$39.00 +246.1%	+252.1%	$550.99M	$250K	N/A	81	Positive News
CABA Cabaletta Bio	2.6456 of 5 stars	$3.24 -4.1%	$15.33 +373.3%	+115.2%	$549.31M	N/A	N/A	50	News Coverage
PROK ProKidney	1.7674 of 5 stars	$1.82 -0.3%	$12.00 +561.2%	-22.5%	$548.72M	$818K	N/A	3

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:CNTB) was last updated on 8/30/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Connect Biopharma (CNTB) Competitors

CNTB vs. ANL, ARTV, CABA, PROK, and ZURA

How does Connect Biopharma compare to Adlai Nortye?

Summary

How does Connect Biopharma compare to Artiva Biotherapeutics?

Summary

How does Connect Biopharma compare to Cabaletta Bio?

Summary

How does Connect Biopharma compare to ProKidney?

Summary

How does Connect Biopharma compare to Zura Bio?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

CNTB vs. The Competition

Connect Biopharma Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Connect Biopharma (CNTB) Competitors

CNTB vs. ANL, ARTV, CABA, PROK, and ZURA

How does Connect Biopharma compare to Adlai Nortye?

Which has preferable earnings and valuation, CNTB or ANL?

Does the media refer more to CNTB or ANL?

Is CNTB or ANL more profitable?

Which has more volatility & risk, CNTB or ANL?

Do analysts prefer CNTB or ANL?

Do insiders and institutionals believe in CNTB or ANL?

Summary

How does Connect Biopharma compare to Artiva Biotherapeutics?

Which has higher earnings & valuation, ARTV or CNTB?

Which has more volatility & risk, ARTV or CNTB?

Do analysts recommend ARTV or CNTB?

Is ARTV or CNTB more profitable?

Do insiders & institutionals hold more shares of ARTV or CNTB?

Does the media prefer ARTV or CNTB?

Summary

How does Connect Biopharma compare to Cabaletta Bio?

Do insiders and institutionals believe in CABA or CNTB?

Which has higher valuation & earnings, CABA or CNTB?

Is CABA or CNTB more profitable?

Which has more volatility and risk, CABA or CNTB?

Do analysts rate CABA or CNTB?

Does the media refer more to CABA or CNTB?

Summary

How does Connect Biopharma compare to ProKidney?

Does the media refer more to PROK or CNTB?

Do analysts rate PROK or CNTB?

Is PROK or CNTB more profitable?

Which has more volatility and risk, PROK or CNTB?

Which has higher valuation and earnings, PROK or CNTB?

Do insiders & institutionals hold more shares of PROK or CNTB?

Summary

How does Connect Biopharma compare to Zura Bio?

Does the media prefer CNTB or ZURA?

Which has stronger valuation & earnings, CNTB or ZURA?

Which has more volatility & risk, CNTB or ZURA?

Is CNTB or ZURA more profitable?

Do analysts rate CNTB or ZURA?

Do institutionals & insiders hold more shares of CNTB or ZURA?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

CNTB vs. The Competition

Connect Biopharma Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools